Loading organizations...
§ Venture Capital · George Town, Grand Cayman, Cayman Islands
Pacific Venture Opportunity Fund operates as an investment vehicle, providing capital to promising companies primarily within the life sciences and biotechnology sectors. The fund strategically supports enterprises developing innovative solutions, evidenced by its participation in significant funding rounds for firms advancing novel technologies like advanced drug delivery systems. It deploys capital to foster growth and accelerate specialized market offerings.
Established as a limited partnership, Pacific Venture Opportunity Fund was formed to capitalize on specific investment opportunities. Its operational model targets high-growth, often high-tech, segments, demonstrating a versatile approach across various stages of company development. This structure identifies and nurtures businesses with substantial potential in specialized markets.
The fund’s portfolio comprises innovative companies requiring capital to advance their research, development, and market penetration. As a key financial partner, Pacific Venture Opportunity Fund enables these entities to bring cutting-edge solutions to fruition. Its vision centers on generating significant financial returns for investors by cultivating transformative businesses poised for impact and growth.
Pacific Venture Opportunity Fund has 1 tracked investment across 1 company. The latest tracked deal is $39.0M Series D in Rani Therapeutics in September 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2017 | Rani Therapeutics | $39.0M Series D | — | Byers Capital, Founders' Co OP, Seven Seven SIX, Susa Ventures, Y Combinator, Justin Mateen, AstraZeneca, Bossanova Investimentos, Buttonwood, Cathay Innovation, Crystal Horizon Investments, GV, Novartis, Pinemount Investments |